New: Introducing the Finviz Crypto Map

Castle Biosciences, Inc.

Contributing Author

Recent Articles by Castle Biosciences, Inc.

Jul-25	Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal CSTL GlobeNewswire
Jul-23	FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx-Melanoma Test CSTL GlobeNewswire
Jul-17	Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture CSTL GlobeNewswire
Jul-14	Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025 CSTL GlobeNewswire
Jun-19	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CSTL GlobeNewswire
Jun-16	Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases CSTL GlobeNewswire
Jun-11	Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention CSTL GlobeNewswire
Jun-04	Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards CSTL GlobeNewswire
May-29	New Data at ASCO 2025 Affirms DecisionDx-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes CSTL GlobeNewswire
May-21	Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference CSTL GlobeNewswire
May-09	Real-World Study Confirms Long-Term Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result CSTL GlobeNewswire
May-07	Castle Biosciences Celebrates Skin Cancer Awareness Month CSTL GlobeNewswire
May-05	Castle Biosciences Reports First Quarter 2025 Results CSTL GlobeNewswire
May-05	Castle Biosciences to Acquire Previse CSTL GlobeNewswire
May-02	New Data at DDW 2025 Further Demonstrates the TissueCypher Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer CSTL GlobeNewswire

Affiliate • Advertise • Theme Settings • Contact • Blog • Help • Privacy • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.